Consensus Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-11 pm EDT			5-day change	1st Jan Change
51.91 ^USD	-2.64%		-2.72%	-7.62%

Jul. 09	Tariff Drama, Minimal Market Reaction
Jul. 09	Exact Sciences Says Its Oncodetect Test to Detect Colorectal Cancer Gets Medicare Coverage	MT

Evolution of the Average Target: Exact Sciences Corporation

Evolution of the Target Price: Exact Sciences Corporation

Changes in Analyst Recommendations: Exact Sciences Corporation

c8.wQXlKFj6jEWifwyuNIlKhS92_yuTR5iPd0CMwBROTrE.-W7WTj-Y2HXKG0HAWsYl8xwvnUr3Iev8ACL-uCIUf9KYMZ9KDqnoCegJbw~c6b3d194225d89b0d93a0b01451cb241

Analysts' recommendations: Exact Sciences Corporation

RBC Raises Price Target on Exact Sciences to $54 From $52, Keeps Sector Perform Rating	May. 02	MT
Mizuho Initiates Exact Sciences at Outperform With $60 Price Target	Apr. 10	MT
Analyst recommendations: Illumina, Boeing, Next, Walmart, Applovin....	Mar. 28
RBC Initiates Exact Sciences at Sector Perform With $52 Price Target	Mar. 13	MT
Barclays Initiates Exact Sciences at Overweight	Jan. 23	MT
BTIG Raises Price Target on Exact Sciences to $75 From $65, Maintains Buy Rating	Nov. 26	MT
Analyst recommendations: Snap, Qualys, Sirius XM, Super Micro Computer, Burberry...	Nov. 06
Analyst recommendations: 3M Company, GM, IBM, Robinhood, Moonpig...	24-10-29
Wells Fargo Global Initiates Exact Sciences at Overweight With $75 Price Target	24-08-28	MT
UBS Cuts Exact Sciences' Price Target to $61 From $66, Maintains Neutral Rating	24-08-01	MT
Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target	24-06-27	MT
BTIG Lowers Price Target on Exact Sciences to $70 From $80, Maintains Buy Rating	24-06-26	MT
Benchmark Upgrades Exact Sciences to Buy From Hold, Sets Price Target at $91	24-01-02	MT
Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating	23-11-03	MT
BofA Securities Cuts Price Target on Exact Sciences to $88 From $110, Maintains Buy Rating	23-10-20	MT
Piper Sandler Upgrades Exact Sciences to Overweight From Neutral, Price Target is $90	23-10-10	MT
Bernstein Starts Exact Sciences With Outperform Rating	23-09-28	MT
Baird Adjusts Price Target on Exact Sciences to $121 From $99, Maintains Outperform Rating	23-08-02	MT
Benchmark Downgrades Exact Sciences to Hold From Buy	23-08-02	MT
Credit Suisse Adjusts Exact Sciences' Price Target to $90 From $75, Keeps Neutral Rating	23-08-02	MT
Goldman Sachs Adjusts Price Target on Exact Sciences to $110 From $85, Maintains Buy Rating	23-07-21	MT
UBS Raises Exact Sciences' Price Target to $99 From $73, Maintains Neutral Rating	23-06-27	MT
Canaccord Genuity Raises Price Target on Exact Sciences to $115 From $92, Maintains Buy Rating	23-06-23	MT
Analyst recommendations: BAE Systems, Berkeley, Burberry, Reinsurance Group, Tesla...	23-06-23
Citigroup Adjusts Price Target on Exact Sciences to $130 From $100, Keeps Buy Rating	23-06-22	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
EXACT SCIENCES CORPORATION			+32.03%
BGI GENOMICS CO., LTD.	-	-	+5.2%
VERACYTE, INC.			+48.94%
ADAPTIVE BIOTECHNOLOGIES CORPORATION			+0.31%
CAREDX, INC			+45.48%
SEEGENE, INC.	-		+33.33%
IOVANCE BIOTHERAPEUTICS, INC.			+472.19%
MARAVAI LIFESCIENCES HOLDINGS, INC.			+85.44%
Average			+90.37%
Weighted average by Cap.			+43.26%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

51.91USD

Average target price

68.54USD

Spread / Average Target

+32.03%

High Price Target

90.00USD

Spread / Highest target

+73.38%

Low Price Target

54.00USD

Spread / Lowest Target

+4.03%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Mizuho Securities
Barclays
BTIG
Benchmark Company
Goldman Sachs
BofA Securities
Piper Sandler
Bernstein
Baird
Credit Suisse
UBS
Canaccord Genuity
Citigroup
Jefferies & Co.
Craig-Hallum
Cowen
Morningstar
Raymond James
SVB Securities LLC
Evercore ISI
SVB Leerink
Wells Fargo Securities
Oppenheimer
Truist Securities